Heterogeneity of the Psychoses: Is There a
Neurodegenerative Psychosis?
by James L. Knoli IV, David L. Qarver, Jane E. Ramberg, Steven J. Kingsbury,
Deborah Croissant, and Barbara McDermott
Whereas etiological heterogeneity of the various types
of schizophrenia has been repeatedly proposed, relatively few attempts have been made to separate the
component diseases. Using a strategy focusing on
bimodal distributions within several relevant domains
of schizophrenia, we demonstrate that currently available data on schizophrenia patients are consistent with
the hypothesis that some of these patients have an
ongoing neurodegenerative disease, whereas others do
not. We review studies (longitudinal and cross-sectional) documenting progressive increases in ventricular size, accelerated loss of brain tissues, progressive
delays in treatment response, and neurochemical
(magnetic resonance spectroscopy) and neurophysiological (P300) indices, all of which are consistent with
ongoing cerebral degeneration in a significant subgroup of schizophrenia patients. These lines of evidence converge on a conceptualization of schizophrenia as being composed of several etiologically distinct
processes, with one subset of psychotic patients evidencing progressive brain degeneration. We conclude
with a discussion of possible etiologies for this condition.
Key words: Heterogeneity, ventricular brain ratio,
phosphoesters, evoked cortical response, degeneration,
apoptosis, drug response.
Schizophrenia Bulletin, 24(3):365-379,1998.
A growing body of evidence indicates that schizophrenia
is not a single disease, but is composed of several etiologically distinct processes that give rise to the hallucinations, delusions, disordered thought processes, and the
volitional defects characteristic of the syndrome. This
concept of heterogeneity has been frequently entertained
in the last decade (Crow 1982; Goetz and van Kammen
1986; Pandurangi et al. 1989; Chang et al. 1990, 1993;
Reprint requests should be sent to Dr. D.L. Garver, Dallas VA Medical
Center (116A), 4500 S. Lancaster Rd, Dallas, TX 75216.
365
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
Peralta et al. 1992; Pulver et al. 1995; Wang et al. 1995).
However, few investigators have rigorously attempted to
separate the proposed etiologic heterogeneity of schizophrenia into its component parts. If schizophrenia is itself
an admixture of several different disease processes, the
data derived from most cohorts of schizophrenia subjects
must also reflect an admixture of several disease
processes. A particularly relevant clinical or biological
finding concerning one of the disease processes in such a
mixed cohort may thus be obscured by the presence of
other psychotic disorders not possessing the abnormality
of interest Detection and specification of one of the diseases is often the result of studying a cohort of patients
particularly enriched in a single disease (Garver et al.
1997).
We previously provided preliminary evidence from
drug response studies (Garver et al. 1988) that the "Group
of the Schizophrenias" is an admixture of psychotic disorders. The group consists of both familial (presumably
genetic) diseases (Kety et al. 1976) and environmentallyinduced phenocopies, some of which may be caused by
neurotropic viruses or other risk factors (Edelman and
Chuong 1982; Mednick et al. 1988; Hollister et al. 19%;
Susser et al. 1996). There is growing evidence for at least
three forms of familial schizophrenia: an already welldocumented early "neurodevelopmental" disorder
(Conrad and Scheibel 1987), a "dopamine psychosis"
(resulting from excess synaptic dopamine) found in goodprognosis psychotics (Garver et al. 1997), and a third
familial psychosis which we now describe, a "neurodegenerative psychosis." Neurodegenerative psychosis
results from an active, ongoing degenerative process especially prominent during the late teens and early twenties,
continuing throughout adult life.
To support this proposition, we selected reports using
data most relevant to neurodegeneration: accelerated
Abstract
Schizophrenia Bulletin, Vol. 24, No. 3, 1998
J.L. Knoll et al.
increases of cerebral ventricular size, premature (agerelated) loss of brain substance, progressive delay in treatment response, evidence of premature dementia, and neurochemical and neurophysiological changes. When viewed
as a whole, the results of these studies support the concept
of neurodegeneration in one subgroup of schizophrenia
patients. We then review possible directions for research
into the etiologies of the neurodegenerative process.
Studies Supporting a Neurodegenerative
Psychosis
Reanalysis of Longitudinal Studies of Cerebral
Ventricular Size. Serial (within-subject) ventricle-tobrain ratios (VBRs) of schizophrenia subjects were
selected from the literature. To assess age-related effects
on changes in ventricular size, only studies that included
the patient's age at index scan (rather than mean ages for
groups of patients) and demonstrated an error for the VBR
method of less than ± 1 VBR unit (see below) were
included in the analysis. Four studies involving a total of
44 schizophrenia patients and 8 controls qualified for
inclusion (Kemali et al. 1989; Woods et al. 1990; Jaskiw
et al. 1994; Vita et al. 1994). To compensate for the varying intervals between index and subsequent scans (1 to 6
years), each patient's VBR was standardized by multiplying the total VBR change by 24 months and dividing by
the number of months between scans to yield the VBR
change per 24 months. VBR data for each subject in the
four studies are listed in table 1.
The "error of the method" in VBR assessments can
result from various factors. For example, the maximum
Table 1. Age and ventrlcle-to-braln ratio (VBR) data from four studies examining serial (wlthlnsubject) VBRs of schizophrenia subjects, involving a total of 44 schizophrenia patients and 8 controls
Kemali etal. 1989
Schizophrenia subjects
Controls
Age
Initial
VBR
Subsequent
VBR
Months
between
VBRs
26
21
36
31
39
29
32
27
36
31
16
24
25
26
37
20
27
21
33
35
19
3.8
2.0
5.8
1.3
5.2
4.3
7.4
2.8
2.0
4.5
4.8
5.3
3.8
1.3
3.3
1.2
1.5
6.4
2.0
4.8
2.3
3.4
2.0
5.0
4.2
5.7
4.3
8.2
3.0
3.6
4.9
5.4
5.1
3.5
4.0
5.6
1.6
1.6
5.7
1.8
4.9
2.3
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
366
Change
In VBR
-0.4
0
-0.8
+2.9
+0.5
0
+0.8
+0.2
+1.6
+0.4
+0.6
-0.2
-0.3
+2.7
+2.3
+0.4
+0.1
-0.7
-0.2
+0.1
0
VBR
change per
24 months
-0.27
0
-0.53
+1.93
+0.33
0
+0.53
+0.13
+1.07
+0.27
+0.04
-0.13
-0.20
+1.80
+1.53
+0.27
+0.07
-0.47
-0.13
+0.06
0
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
Progressive Increase in Ventricular Size in Schizophrenia. Increasingly sophisticated brain-imaging techniques (pneumoencephalography, computerized axial
tomography [CAT], and magnetic resonance imaging
[MRI]) have shown that a substantial number of young
adults with schizophrenia have cerebral ventricular
enlargement that cannot be accounted for by substance
abuse, trauma, or other known causes of brain atrophy (for
a review, see Coffman 1989). The critical question is
whether such cerebral ventricular enlargement is a consequence of some early neurodevelopmental event and is
thus static in adulthood, or whether such enlargement is
ongoing and progressive during the course of the illness. If,
in an adult with schizophrenia, the size of the ventricles
progressively increases as the illness progresses at a rate in
excess of that found in controls, an active progressive
degenerative process (as opposed to a now static early neurodevelopmental abnormality) can be reasonably proposed.
Schizophrenia Bulletin, Vol. 24, No. 3, 1998
Heterogeneity of the Psychoses
Table 1. Age and ventrlcle-to-braln ratio (VBR) data from four studies examining serial (wlthinsubject) VBRs of schizophrenia subjects, Involving a total of 44 schizophrenia patients and 8
controls—Continued
Jaskiwetal. 1994
Schizophrenia subjects
Age
Subsequent
VBR
Months
between
VBRs
18
36
36
32
25
1.9
1.4
2.0
3.3
1.9
1.7
1.5
1.8
3.2
2.1
37
37
37
37
37
-0.2
+0.1
-0.2
-0.1
+0.2
-0.13
+0.06
-0.13
-0.06
+0.13
25
23
20
27
31
20
20
24
37
3.8
7.1
7.3
8.2
11.7
12.8
15.2
15.8
7.6
6.9
8.0
13.4
9.1
15.0
19.1
18.4
18.2
7.3
24
30
20
12
42
30
48
24
36
+3.1
+0.9
+6.1
+0.9
+3.3
+6.3
+3.2
+2.4
-0.3
+3.10
+0.72
+7.32
+1.80
+1.89
+5.04
+1.60
+2.40
-0.20
31
17
39
20
31
32
14
19
6.2
14.0
2.6
10.2
8.0
2.0
6.0
10.2
5.8
11.2
7.3
8.2
7.0
0.6
6.8
10.2
72
72
72
72
72
72
72
72
-0.04
-2.8
+4.7
-2.0
-1.0
-1.4
+0.8
0
-0.13
-0.93
+1.57
-0.67
-0.33
-0.47
+0.27
0
Change
In VBR
'
Vita etal. 1994
Schizophrenia subjects
24
-0.10
-0.1
1.0
1.1
18
-0.32
1.7
-0.4
30
2.1
21
-1.07
2.1
3.7
-1.6
36
19
-0.23
32
7.7
-0.3
8.0
25
-0.2
-0.17
9.2
28
9.4
28
+0.2
24
+0.20
6.1
5.9
19
24
7.2
+0.60
+0.6
6.6
18
+0.37
+0.4
9.4
32
26
9.0
+0.2
+0.10
9.0
46
21
8.8
Note.—To assess age-related effects on changes in ventricular size, only studies that included patient age at index scan (rather than
mean ages for groups of patients) and that showed an error of the method of less than ± 1 VBR unit were included In the analysis.
patients with anorexia nervosa [Artman et al. 1985] and in
chronic alcoholics undergoing alcohol withdrawal [Carlen
et al. 1978]), the decrement in VBR found in schizophrenia subjects should provide an estimate of half the error of
the method. Since the other half of the error cannot be
estimated from data being assessed for a frank increase in
VBR associated with degeneration, it seems most reasonable to estimate the total error by reflecting the decrement
both negatively and positively around the 0 (mean error)
axis. The estimated 98 percent confidence level of error of
the VBR method is then 0 ± 2 standard deviations (SD) of
ventricular area is derived from scans from which only
every 10th slice is projected onto radiographic film for
assessment. Thus, it is unlikely that the slice assessed
reflects the largest VBR. Furthermore, slight variations in
head positioning within the CAT result in larger exposure
of lateral ventricles on one side of a slice relative to the
other. We first examined those patients in which the VBR
appeared to decrease from index to subsequent assessment. Since ventricular volume would physiologically not
be expected to decrease in schizophrenia subjects
(although ventricular change has been documented in
367
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
Woods etal. 1990
Schizophrenia subjects
VBR
change per
24 months
Initial
VBR
J.L. Knoll et al.
Schizophrenia Bulletin, Vol. 24, No. 3, 1998
Figure 2. Change in ventrlcle-to-brain ratio
(VBR) In relation to age
the mean error; in this study, the error was -0.97 to +0.97.
Twelve of the 44 VBRs demonstrated VBR changes outside of the error of the method.
Normality of the VBR change distribution and normality of the VBR distribution with common transformations were assessed by a Lillifores test (SYSTAT for
Windows 1992). Even with transformations, the distribution of VBR changes differed from normal at the p < 0.001
level (figure 1). Cluster analysis with K-means splitting
(SYSTAT for Windows 1992) estimated two populations of
VBR change, with 32 of the 44 schizophrenia subjects
(73%) essentially encompassed within the aforementioned
error of the method, having a mean ± SD of -0.06 ± 0.41
(range -1.07 to 0.72). A second cluster of patients with
VBR change outside the 98 percent confidence level of
method error (n = 10), contained all but two of the remaining schizophrenia subjects. This cluster had a mean VBR
change of 1.85 ± 0.53 (range 1.04 to 3.10). Two additional
VBR change outliers had the highest VBR change (mean
6.18 ± 1.14, range 5.04 to 7.32) and were among the three
youngest patients (figure 2). The combined second and
third (outlier) clusters (n = 12, 27%) demonstrated clear
Schizophrenics showing:
•
v
*
35
40
45
evidence of progressive VBR enlargement during the
interval between VBR measurements.
hi those schizophrenia patients with increasing ventricular size (n = 12), there was a negative correlation
between age and change in VBR (rp = -0.627, p = 0.029).
Even when the two outlying patients were excluded, the
remaining patients between the ages of 22 and 41 continued to show a strong negative correlation between VBR
and age (r = -0.732, p = 0.026). The greatest change in
VBR in these patients appeared to occur in those whose
index VBR was performed in their late teens or early
twenties (figure 2).
Thirty-two of the 44 (73%) schizophrenia subjects
examined in these samples were within the error of the
VBR method and showed no evidence of a progressive
expansion of VBR. However, 20 of these 32 (62.5%),
although showing no progression of ventricular size (figure 2), had index VBRs already greater than 2 SD outside
the mean of the controls (mean 2.4 ± 1.1 SD). Continuous
expansion of VBR would not be expected in individuals
with large static ventricles if the etiology of large VBRs
6 -
4 -
2 -
II
4
30
All data standardized to a 2-year interval. • = schizophrenia
patients showing Increasing VBR throughout young adult life,
maximal in teens and early twenties. The curve is the best fit of
the data using a second-order regression (SigmaPlot for Windows
[1986-1994]); V » schizophrenia patients showing enlarged VBR
(> 2 SD of age- and sex-matched controls) that are static and are
characteristic of a putative early neurodevelopmental psychosis;
T = schizophrenia patients without VBR enlargement (characteristic of still other psychoses). Data from Kemali et al. (1989),
Woods et al. (1990), Jaskiw et al. (1994), and Vita et al. (1994).
10-,
Piytfcot i * c
no cbtmgt to VBR
(N-32)
23
age at index VBR
Figure 1. Frequency distribution of changes In
ventrlcle-to-braln ratios (VBRs) In schizophrenia
patients
II
20
6
Piycbobc* lowing
(N-12)
change in VBR/2 years
Data fails to meet criteria for a normal distribution (Lillifores p <
0.001), but fits a bimodal pattern with two outliers (K-means splitting). The data are consistent with two (or perhaps three) distinguishable populations within the syndrome of schizophrenia. An
active, progressive enlargement of VBR is shown in the upper
groups.
368
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
1J
iaonakiVBRi(N-l2)
Miatiy<al*iedVBJU(N-lS)
noVBItahrfemeM(N-17)
Schizophrenia Bulletin, Vol. 24, No. 3, 1998
Heterogeneity of the Psychoses
ologically altered," rather than at the 3-year (or other
duration) followup scan. The preponderance of such physiological changes at the time of the first scan followed by
partial recovery associated with neuroleptic treatment at
the time of the subsequent scans would also result in a
mean VBR decrement (rather than expansion) from initial
to followup scans.
Cross-Sectional Studies of Brain Ventricles in Schizophrenia Subjects. Cross-sectional reduction of ventricular areas or volumetric data, when correlated with
increasing age, can also provide potentially useful information relevant to a premature, ongoing degenerative
process. However, such cross-sectional data needs to be
interpreted with caution given the many treatment variables and the life differences between schizophrenia and
normal comparison groups.
The brain's third ventricular areas can be reliably
measured on CAT scans. As with lateral ventricles, third
ventricular enlargement is not detectable by CAT scans in
normal controls until the sixth or seventh decade of life
(Barron et al. 1976). An age-associated increase in third
ventricular size measured by CAT scans before the age of
55 in a subgroup of psychotic patients would thus also be
consistent with a premature degenerative process.
Schwarzkopf et al. (1990) found age to be correlated
with the third VBR in a cohort of schizophrenia subjects
between the ages of 18 and 50 (rp - 0.54, p < 0.05).
Kaplan et al. (1990) reported that third ventricular enlargement in adult psychotic patients is closely related to age,
but only in a subgroup of psychotic patients. This latter
group of patients showed third ventricular areas that
increased with age (rp - 0.83, p < 0.01) over a range of 19
to 55 years (figure 3); the slope of this change was significantly greater than the slope of rapidly responsive psychotic patients and controls within the same age range
(repeated measures analysis of variance [ANOVA]; F =
5.71; df= 1, 43; p = 0.021). (There was no significant difference between the slopes of normals and of other rapidly
responsive psychotic patients [repeated measures ANOVA:
F = 0.175; df= 1, 30; p = 0.679].) As noted, in the normal
population there is a positive correlation between age and
ventricular size (measured by CAT scans) that begins only
in the sixth and seventh decades of life (Barron et al.
1976). In this subgroup of psychotic patients, the positive
correlation was in effect shifted more than 20 years to the
left Although these psychotic patients could not be symptomatically distinguished from other psychotic patients,
they could be identified by their delayed responsiveness to
neuroleptic medication (Garver et al. 1988). This subgroup
of patients with clear age-related premature increases in
third ventricles responded moderately well to neuroleptic
medication (with more than a 55% reduction of psychotic
Additional Variables That Might Influence Serial VBR
Determinations. Treatment with conventional neuroleptics has been shown to result in increased volume of the
caudate (Chakos et al. 1994). Such neuroleptic- associated
enlargement of the caudate or other structures at the second imaging session and perhaps not the first generally
would be expected to result in a decrement in ventricular
volume and would work against the findings of ventricular
expansion documented herein. While neuroleptic treatment
may cause a reduction in volume of certain areas of the
brain and concomitant enlargement of ventricular space,
the limited available data appear to suggest the opposite.
The possibility that treatment with neuroleptics retards
the progression of a neurodegenerative process has been
suggested in part as a consequence of data demonstrating a
better outcome in patients treated earlier in die course of
their illness and treated more consistently with neuroleptics throughout the course of their illness (Wyatt 1991). If
true, this would also work against the detection of ventricular expansion in patients treated with neuroleptics.
Physiological variations causing a state-associated
change in ventricular size have been documented in
patients with anorexia nervosa (Artman et al. 1985) and in
chronic alcoholics undergoing alcohol withdrawal (Carlen
et al. 1978). One might suspect severe dehydration or
electrolyte imbalance to be associated with state-related
changes in ventricle size. However, if such physiological
changes are present in schizophrenia patients they would
be expected to be present more often at the initial scan,
when the patient was most acutely ill and perhaps "physi-
369
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
was related to an early neurodevelopmental abnormality
rather than an ongoing neurodegenerative process.
Although several serial studies of ventricular volume
using magnetic resonance imaging (MRI) and volumetric
techniques are in progress, only two series have been
reported in the literature. DeLisi et al. (1992, 1995), following first-break schizophrenia subjects and controls for
4 years, reported more than a 2.4-fold rate of left ventricular expansion (per total brain volume) in schizophrenia
subjects as compared with controls, suggesting the presence of an active degenerative process. No difference in
the rate of change was found in right ventricular volumes
(per total brain volume). Lieberman et al. (1996) found
that schizophrenia patients with expansion of ventricles
over an 18-month period following a first psychotic
episode had a poorer treatment outcome than patients
whose ventricles were static. It has recently been reported
that elderly people with schizophrenia and a continuing
VBR increase have a more severe illness that is not
responsive to drugs and is accompanied by premature
dementia of a non-Alzheimer's type (Davis 19%, and personal communication December 1995).
Schizophrenia Bulletin, Vol. 24, No. 3, 1998
J.L. Knoll et al.
Figure 3. Third ventricular area, delayed
responsive psychotlcs, and age
50 -i
45 -
•
o
•
delayedresponsivepsychotic* (N=13)
normal controls (N»20)
otherpsycnotfcs(N*12)
40 35 30 -
> 20 -
10 5 0
10
20
30
40
50
60
70
»
age
• = delayed responsive psychotics; V - other drug-responsive
psychotics (dopamine and lithium-responsive psychotics); O =
normal controls; (
) = older normal controls. Data from
Kaplan et al. (1990) and Barron et al. (1976). Age—3rd ventricular
area relationship is shifted more than 20 years to the left in the
delayed responsive psychotics.
symptoms) but only after 9 to 45 days (mean of 18.5 ±
10.5 SD) of neuroleptic treatment
The highly correlated age-ventricular size relationship seen in these delayed-responding psychotic patients
throughout the third to fifth decades of life is indicative of
a greater than 20-year shift to the left of the age-ventricular size relationship found in normal controls. This study
further suggested that it may be possible to identify this
"neurodegenerative psychosis" by a specific neurolepticresponse feature: delayed (greater than 8 days) response
to conventional antipsychotic drugs during the first
decade of the illness (Garver et al. 1988). Ventricular
enlargement did not occur in the rapidly responsive
dopamine psychotic patients (Kaplan et al. 1990). Others
(Weinberger et al. 1980; Luchins et al. 1984; Pandurangi
et al. 1989; Frecska et al. 1995; Lieberman et al. 1996)
have also reported that patients without ventricular
enlargement show a more rapid and better response to
antipsychotic medication.
Progressive Resistance to Neuroleptic Treatment.
Upon readmission for a subsequent psychotic episode, five
out of five of our delayed-responding psychotic patients
required additional days of neuroleptic treatment to achieve
a response similar to that found during the previous
episode (Garver et al. 1988). Other studies have revealed
that with each psychotic episode, some schizophrenia subjects become progressively resistant to antipsychotic drugs,
with further delays in response times, a progressively
poorer antipsychotic outcome (Wyatt 1991; Lieberman et
al. 1993, 1996; Loebel et al. 1995), and perhaps eventual
schizophrenic dementia (Purohit et al. 1993). Such patients
have difficulty regaining previous levels of functioning and
show evidence of a progressively deteriorating illness.
Elderly schizophrenia subjects with such a debilitating
nonresponsive schizophrenic illness have recently been
reported to display expanding ventricular volumes (Davis
1996, and personal communication December 1995).
Decreased Volume of Brain Tissues in Schizophrenia.
The literature is replete with studies documenting diminished size of structures within the brains of schizophrenia
subjects as compared with normal controls. Cortical atro-
370
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
phy has been repeatedly described (Vita et al. 1991;
Waddington et al. 1991; Gewirtz et al. 1994) and has been
associated with enlarged ventricles (Vita et al. 1988;
D'Amato et al. 1992). Similar associations have been
noted between ventricular enlargement and both diminished cerebellar size (Coffman and Nasrallah 1985;
Nasrallah et al. 1985; Sandyk et al. 1991) and diminished
size of the hippocampus (Stevens 1992). However, such
studies do not differentiate between progressive degenerating (atrophic) and now-static, early developmental (failure-to-fonn) processes.
There are, however, two published studies of schizophrenia subjects that relate such differences in brain tissue
volumes with age, and one serial study of changes in
brain tissue volume over a 4-year period. MRI volumetric
examinations of the left posterior temporal gyrus
(O'Donnell et al. 1995) and of the cortex (Gewirtz et al.
1994) were highly related to age in some schizophrenia
subjects, but not in controls. As noted previously, such
cross-sectional data need to be interpreted with caution
owing to secondary treatment and life differences between
schizophrenia and normal comparison groups. From
within-subject serial volumetric MRI examinations (with
age-matched controls), DeLisi et al. (1995) reported a significantly increased rate of atrophy in the left temporal
lobe and in both left and right cerebral hemispheres of
schizophrenia subjects. Reanalysis of the rate of volume
change for both right and left hemispheres found a nonnormal distribution in schizophrenia subjects (KolmogorovSmirnov one-sample test using a standard normal distribution, p = 0.001), even after the exclusion of an outlier.
These data were also consistent with a multimodal distribution of hemispheric atrophy, the upper mode consistent
with an ongoing, active neurodegenerative process.
Schizophrenia Bulletin, Vol. 24, No. 3, 1998
Heterogeneity of the Psychoses
These response patterns, seen in some schizophrenia subjects, again suggest a neurodegeneran've process.
Excess Products of Membrane Degeneration in Some
Schizophrenia Subjects. MRS may be able to identify
patients with an active, ongoing neurodegenerative
process from the larger group of schizophrenias.
Phosphorus MRS ( 31 P-MRS) is a noninvasive tool that
permits the quantitation of select substances related to
phosphorus and phospholipid metabolism in vivo. It can
be used to quantify critical phospholipids, which are the
primary constituents of cellular membranes. In particular,
the synthesis and breakdown of membrane phospholipids
can be estimated by quantification of the phospholipid
membrane building blocks versus the breakdown products
of membrane metabolism. Phosphomonoesters (PMEs),
such as phosphoethanolamine and phosphocholine, are
the precursors of membrane phospholipids. The phosphodiesters (PDEs), including glycerol 3-phosphoethano-
371
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
Neurodegeneration and Electrophysiological Changes.
The P300 cortical event-related potential (ERP) elicited
by the "odd ball stimulus paradigm" is generated in the
posterior temporal gyrus. Latency of the P300 cortical
ERP is known to increase during normal aging and is further accelerated in individuals with such neurodegenerative disorders as dementia, Alzheimer's disease, multiple
sclerosis, Huntington's chorea, and Parkinson's disease
(O'DonneU et al. 1995).
O'Donnell et al. (1995) found that some schizophrenia subjects also show age-associated increased latency of
the P300. Though some schizophrenia subjects had P300
latencies similar to that of normal controls, one schizo-'
phrenia subgroup manifested significantly longer agerelated latencies that appeared to be inversely correlated
to the size of the posterior temporal gyrus. In comparison
with age-matched controls, this schizophrenia subgroup
exhibited an age-related shift to the left of the P300. This
finding parallels the observation of the more than 20-year
shift to the left reported in third ventricle-age relationships in the subgroup of psychotic patients who manifest
the delayed antipsychotic response to neuroleptic drugs
(Kaplan et al. 1990). This is also consistent with the findings of changes in the ratio of synthesis and breakdown of
membrane phospholipids described by magnetic resonance spectroscopy (MRS) in some schizophrenia patients
(see below). As noted previously, cross-sectional studies
relating age to ventricular size, temporal lobe volume, or
P300 must always be interpreted particularly cautiously
given the many treatment-related and life-style differences between some patients with schizophrenia and comparison groups.
lamine and glycerol 3-phosphocholine, are the breakdown
products of membrane phospholipid metabolism. An
excess of breakdown products (PDE) as compared with
building blocks (PME), resulting in an elevated
PDE/PME ratio, is indicative of ongoing tissue degeneration (Pettegrew et al. 1993), as opposed to tissue growth
or equilibrium.
The PDE/PME ratio in the frontal cortex of schizophrenia patients from seven age-specified cohorts and
their age-matched controls has been described in the
recent literature (Pettegrew et al. 1991; Fujimoto et al.
1992; Deicken et al. 1994; Shioiri et al. 1994; Stanley et
al. 1994 [two cohorts]; Kato et al. 1995). The PDE/PME
of each schizophrenia cohort was standardized for age and
sex by dividing each cohort's ratio by the PDE/PME of
the investigator's own age-matched controls. If a schizophrenia subject had excess PDE or a relative deficiency of
PME as compared with controls, the ratio in that schizophrenia cohort would be greater than 1.0. Each of the
cohorts was assumed to be composed of a mixture of
degenerative psychotic patients and other nondegenerative psychotic patients. In such a mixture, the "signal" of
the degenerative process, present in only a subgroup of
the psychotic patients, must be sufficiently strong to be
detected oveT the "noise" generated by the remaining nondegenerative psychotic patients.
Mean age-corrected PDE/PME ratios were significantly elevated in the three youngest schizophrenia
cohorts investigated (Pettegrew et al. 1991; Stanley et al.
1994; Kato et al. 1995) (figure 4). These were cohorts
with a mean age of 22 to 30 years—similar to the age of
patients showing maximum changes in VBR (figure 2).
Thus, the PDE/PME signal from a degenerative group of
psychotic patients within a presumed mixture of younger
schizophrenia subjects was sufficiently strong to raise the
mean cohort PDE/PME as compared with age-matched
controls. Within the mixture of psychotic patients aged 31
years and older, there was still a sufficient signal from
degenerative psychotic patients to provide PDE/PME
ratios in excess of the age-matched controls in two of the
four older cohorts, similar to the continuing but smaller
increases in VBR in the subgroup of degenerative psychotic patients seen in figure 2.
Recently, Stanley et al. (1995) have characterized the
PME building blocks as being diminished throughout the
course of schizophrenia, with a particular increase in
PDEs during the early part of the illness. Diminished
PMEs in some schizophrenia subjects throughout the
course of the illness suggest impairment of the usual
ongoing process of cell repair and regeneration. Since
central nervous system (CNS) tissues, like those in the
periphery, are constantly undergoing programmed cell
death (apoptosis; see below), the decrement of regenera-
Schizophrenia Bulletin, Vol. 24, No. 3, 1998
J.L. Knoll et al.
2.00 -i
1.75 -
fI
1.80 -
1.28 -
1.00 -
0.75 -
0.50
2 0 2 2 2 4 2 0 2 8 3 0 3 2 3 4 3 0 3 8 4 0
42
mean age in years
Each cohort corrected for age and sex by dividing PDE/PME
ratios of patients by those of age- and sex-matched controls.
Displayed ratios greater than 1.0 (•) indicate increase in
PDE/PME ratios; (O) indicates nonsignificant decrease in
PDE/PME ratios. Data from Pettegrew et al. (1991), Fujimoto et
al. (1992), Deicken et al. (1994), Shioiri et al. (1994), Stanley et
al. (1995) (two cohorts), and Kato et al. (1995).
Possible Etiologies for a
Neurodegenerative Schizophrenia
tion and repair, as reflected by a paucity of PMEs, results
in a progressive, chronic net loss of brain tissue. An
increase in age-associated neuropil loss during the early
twenties in some schizophrenia subjects may be reflected
by the early temporary increase in PDEs.
The data from the age-corrected 31 P-MRS studies,
from a putative mixture of neurodegenerative and other
psychoses, are strikingly parallel to the aforementioned
changes in VBR in some of the schizophrenia subjects
(figure 1), with higher PDE/PMEs and a greater rate of
ventricular expansion in the early twenties followed by
evidence of sustained, but less elevated ratios or ventricular volume changes. The data are also consistent with the
age-associated increase in third ventricular areas
described in the delayed responsive psychosis (figure 3).
These findings provide very strong support for the concept of acute tissue loss in the late teens and early twenties, and ongoing failure of neuropil maintenance in one
of the disorders that make up the schizophrenia syndrome.
The existence of a neurodegenerative subtype of schizophrenia raises other issues. The cause of the degenerative
process that appears to occur in the brains of some schizophrenia subjects remains unknown. There are, however,
substantial leads, and explorations concerning the nature
of this process are already ongoing. As the etiology of this
process becomes better understood, it is likely that new
therapeutic approaches will be directed more specifically
toward the causes of the neurodegenerative process that
produces such psychiatric morbidity. A very important
lead focuses on the processes of neuropil turnover tissue
maintenance and elimination. Apoptosis occurs when an
intracellular, genetically encoded death program is
released from inhibition. A variety of neurotrophins present in a cellular environment ward off this genetically
induced apoptotic cascade. Certain forms of free-radical
toxicity also appear to be associated with the release of
apoptosis programs.
Degeneration and Apoptosis. Brain tissue can degenerate by either necrosis or apoptosis. Necrosis follows injury
and consists of cellular swelling, lysis, and the subsequent
spilling of cellular contents into the extracellular space. An
Summary of Studies Supporting a Neurodegenerative
Psychosis. The evidence presented here indicates that
schizophrenia is not a homogeneous disorder. Rather,
372
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
these studies reveal heterogeneous schizophrenia cohorts.
Some of these schizophrenia subjects have cerebral ventricles that enlarge over time; some show a more than 20year shift to the left of the usual age-related third ventricular area relationship accompanied by a delayed
neuroleptic response. Some appear to show a similar agerelated decrement in temporal lobe volume. Some evidence progressive loss of cerebral cortical and temporal
lobe volume. One schizophrenia subgroup demonstrates
increased latency of the P300. Some schizophrenia subjects show age-related increases in PDE/PME ratios.
Some appear to experience progressive difficulty in
responding to neuroleptics during repeated hospitalizations, with the eventual development of a severely debilitating "dementia praecox."
The most parsimonious explanation for these phenomena would be a single degenerative disorder, rather
than many. Proof that these subgroups indeed represent
schizophrenia subjects with a single progressive neurodegenerative disorder awaits comprehensive studies that
would confirm, in the same group of patients, progressive
ventricular enlargement, progressive cerebral atrophy,
higher PDE/PME ratios, delayed P300s, and a progressively delayed treatment response.
Figure 4. Phosphodlester (PDE) and phosphomonoester (PME) ratios (PDE/PME) In the frontal
cortex In age-Identified cohorts of syndromally
Identified schizophrenia patients
Heterogeneity of the Psychoses
Schizophrenia Bulletin, Vol. 24, No. 3, 1998
ERPs (Feinberg 1982/83). Some adults with schizophrenia show an exaggeration of exactly these physiological
markers of adolescent pruning: decreased frontal lobe
metabolism, increasing deficits in slow-wave sleep, and
delayed latency or reduced amplitude of ERPs (Keshavan
et al. 1994; O'Donnell et al. 1995). These features, coupled with a frequent onset of psychoses during late adolescence, may be evidence of a pathological extension of
the adolescent pruning process into adulthood.
Pathological extension of pruning is consistent with a
continued apoptotic process associated with increased
PDEs on 31 P-MRS in some schizophrenia subjects in
their early twenties. While the factors underlying the control of normal synaptic pruning and its potential pathological extension are poorly understood, extended pruning
and elevations of PDEs may be a result of apoptosis occasioned by the failure of protective neurotrophins.
Neurotrophic Factors and Schizophrenic Neurodegeneration. Neurotrophic factors (such as nerve
growth factor [NGF], brain-derived neurotrophic factor,
neurotrophin-3, neurotrophin-4/5, and others), are produced by a variety of CNS cells. They inhibit the spontaneous initiation of death programs as they interact with
neuronal membrane proteins (Barde 1994). Perez-Polo et
al. (1978) reported that the cerebrospinal fluid of some
schizophrenia subjects contains a paucity of NGF as
determined by immunoassay (30% of normals) and bioassay (5% of normals). Bersani et al. (1996) found significantly lower levels of NGF in the plasma in schizophrenia
subjects (both drug free and neuroleptic treated) compared with normal controls. A decrement of one or more
NGFs in adults with schizophrenia may also lead to apoptotic degeneration.
Free Radical and Detergent-Induced Cellular Injury
in Schizophrenia. Free radical injury is accompanied
by the appearance of reactive oxygen radicals (RORs) that
are formed as a consequence of tissue oxidation. Recent
evidence has implicated free radicals as triggers of some
forms of apoptosis (Wood and Youle 1994). RORs are
generated as a consequence of a number of metabolic
processes within the CNS. Many of the processes feed
back upon themselves, producing an ever-renewing cascade of fresh oxidation and ROR products.
Unsaturated fatty acids, enriched in the brain, are
especially susceptible to oxidation. The interaction of
RORs with membrane unsaturates produces a range of
products, including free fatty acids and lipid peroxidases.
Lipid peroxidases continue to degrade more unsaturated
fatty acids autocatalytically (Cotran et al. 1989). Released
free fatty acids themselves have detergent properties,
altering membrane fluidity and integrity, uncoupling
Pathological Extension of Synaptic Pruning and
Schizophrenia. A considerable amount of literature has
suggested that schizophrenia may be, in part, a disorder of
late neurodevelopment gone awry. Later phases of neurodevelopment (during and following puberty) are associated with the pruning of redundant, juvenile synapses and
cellular disappearance, both of which then stabilize during
normal adult life (Huttenlocher 1979). Such pruning has
been reported to be associated with decreased oxygen use,
decreased total sleep duration, and increased latency of
373
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
inflammatory response ensues, including glial proliferation. During apoptosis, nucleus and cytoplasm condense
and fragment, with the fragments being rapidly phagocytized by neighboring cells or macrophages. No inflammatory process or gliosis occurs. Even large-scale apoptosis
is often histologically inconspicuous (Kerr et al. 1972).
In the embryonic development of the CNS, apoptosis
plays a critical role in determining which cells and neuropil (axons, dendrites) will survive. Cells that project
onto appropriate target cells and receive neurotrophins
from the target cells are sustained. Inappropriate projections onto cells that cannot provide the necessary neurotrophic factors result in programmed elimination
(Cowan et al. 1984). It has been estimated that 50 percent
of neurons and their projections once present in the CNS
have disappeared via apoptosis by early adulthood (Raff
et al. 1993).
However, apoptosis does not cease upon the completion of neurodevelopment or with the termination of the
normal synaptic pruning of late adolescence. Rather,
apoptosis continues throughout the life of the organism
(Barde 1994). Cells and neuropil are constantly eliminated via apoptosis, and neuropil is often replenished by
regeneration. When regeneration and apoptosis are in
equilibrium, tissues are stable. When apoptosis is accelerated or regeneration is reduced, tissue loss is apparent.
Techniques that quantify degeneration and regeneration may be particularly useful in studying the parameters
associated with neurodegeneration. One such technique is
31
P-MRS. As noted earlier, a relative decrement in PMEs
is associated with a partial failure in the process of maintenance and regeneration. Excess PDEs may be associated
with an elevated rate of cellular or neuropil death. The
elevated PDE/PME ratio and progressive decrease of
brain substance in some schizophrenia subjects can therefore be associated with an acute apoptotic process in the
late teens or early twenties (accompanied by elevated
PDEs), followed by a continuous partial failure of maintenance and regeneration (accompanied by chronic diminished PMEs). Together, the processes may result in an initially acute, then slow chronic loss of brain volume and
consequent increase in ventricular size.
Schizophrenia Bulletin, Vol. 24, No. 3, 1998
J.L. Knoll ct al.
Glutamate-Associated Neurodegeneration.
Conclusions
Converging evidence from a variety of lines of research
suggests that nested among the group of syndromal schizophrenias is an etiologically distinct form of psychosis
that provides evidence of progressive premature atrophy
of brain substance, increasing cerebral ventricular size,
failure to maintain cellular membrane phospholipids, premature neurophysiological changes (P300), and delayed
response to neuroleptic treatment. Although presenting
with hallucinations, delusions, and diought disorders similar to those of other people with schizophrenia, these psychotic patients appear to suffer from a neurodegenerative
disorder. Unlike other forms of psychosis, there is no evidence that this disorder is associated with a functionally
hyperactive dopamine system (Garver et al. 1997) or wiui
early neurodevelopmental pathology.
The
amino acid neurotransmitter glutamate is neurotoxic at
high tissue concentrations (Rothman and Olney 1986).
Excess glutamate activity is associated with neurodegenerative processes of several CNS disorders, including
Huntington's disease (Shoulson 1983) and Parkinson's
disease (Klockgether and Turski 1993), as well as with
secondary excitotoxic degeneration following stroke
374
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
(Simon et al. 1984) or spinal cord injury (Collins and
Olney 1982). Parkinson's-associated degeneration of the
striatal projection neurons, accompanied by impaired
dopamine activity, bears all the characteristics of glutamate-induced apoptosis. Such glutamate-induced striatal
apoptosis can be prevented in animal models of
Parkinson's disease by administering glutamate antagonists (or by interrupting cortical-striatal glutamate tracts)
(Mitchell etal. 1994).
Despite intriguing leads from animal studies (Olney
and Farber 1995), only limited evidence supports glutamate-induced neurotoxicity in schizophrenia. Indirect evidence comes from observations mat neurons, presumably
innervated by glutamate, have decreased uptake sites for
uieir primary neurotransmitters and may therefore be partially destroyed by the excitotoxic effects of glutamate.
There are decreased uptake sites for gamma-aminobutyric
acid (GABA) on GABA neurons presumably once innervated by glutamate neurons in the putamen (Simpson et
al. 1992) and reduced dopamine re-uptake sites on
dopamine neurons in the prefrontal cortex (Hitri et al.
1995). Hitri et al. (1995) found that the decrease in
dopamine transport activity is inversely related to age in
people with schizophrenia, whereas age- and sex-matched
controls showed no such age-associated reduction over an
age span of 19 to 77 years. The Hitri study documents an
age-related, progressive decrease in dopamine cells (if the
dopamine transporter is a reliable marker for the quantity
of dopamine neurons). The only other known evidence of
possible transsynaptic degeneration putatively associated
with glutamate hyperactivity is the observation of
decreased glutamate binding in die medial temporal cortex of schizophrenia subjects (Kerwin et al. 1988; Deakin
et al. 1989).
oxidative phosphorylation and ion balance (Anderson and
Thomas 1994). Certain unsaturated fatty acids (especially
20- and 22-carbon) are deficient in the plasma and red
blood cell membranes of some schizophrenia subjects
(Kaiya et al. 1991; Yao et al. 1994), and their concentrations appear to be bimodally distributed (Glen et al.
1994), suggesting that a subgroup of schizophrenia
patients may be particularly susceptible to free radical
oxidation of membrane unsaturates.
Phospholipase A 2 (PLA2) activity has been found to
be elevated in the plasma (Gattaz et al. 1987, 1990; Albers
et al. 1993; Noponen et al. 1993) and platelets (Gattaz et
al. 1995) of some schizophrenia patients. PLA 2 is an
enzyme that catalyzes the hydrolysis of membrane phospholipids to release free fatty acids and other cytotoxic
products, such as lysophosphatidylcholine (Anderson and
Thomas 1994). Such cytotoxins further accelerate the
breakdown of membrane phospholipids. Increased
lysophosphatidylcholine has been described in the
platelets of some schizophrenia subjects (Pangerl et al.
1992), and excess phospholipid breakdown products have
been found in post-mortem studies of the frontal lobes of
some schizophrenia subjects (Horrobin et al. 1991).
Studies of peroxidases, ROR-scavenging enzymes,
antioxidants, and products of such lipid peroxidation have
been reported in schizophrenia. Increased plasma lipid
peroxidases have been found in some schizophrenia subjects (Prilipko 1984). A deficiency of the scavenger
enzyme superoxide dismutase was reported in the red
blood cells of some first-episode, drug-naive schizophrenia
subjects (Mukherjee et al. 1994). An association between a
deficiency in the scavenger enzyme glutathione peroxidase
and an excess of an end product of lipid peroxidation, thiobarbituric-acid-reactive malonyldialdehyde products has
been reported in the plasma of some people with schizophrenia (Mahadik et al. 1995; Scheffer et al. 1995).
The notion that a neurodegenerative psychosis is associated with an apoptotic process triggered by free radical
oxidation of susceptible unsaturated phospholipids awaits
further confirmatory studies. Such studies will need to
examine simultaneously, in the same subjects, changes in
ventricular size, alterations in PDEs (and perhaps PMEs),
membrane phospholipid unsaturation, lipid peroxidases,
membrane-derived cytotoxins, and PLA2 activity.
Heterogeneity of the Psychoses
Schizophrenia Bulletin, Vol. 24, No. 3, 1998
Identification of such a degenerative schizophrenia
may be possible even before the first psychotic episode
through MRS studies of ratios of phospholipid degradative products to precursors in the brains of psychotic
patients: Keshavan et al. (1991) found an elevated
PDE/PME ratio in a "control" patient who developed
symptoms of schizophrenia 2 years later. However, the
specificity and sensitivity of this MRS method for detecting a degenerative psychotic disorder has not yet been
reported in relation to the "gold standard" of progressive,
increasing ventricular size measured with serial CAT or
MRS examinations.
To date, the best clinical correlate of the degenerative
process may be a delayed antipsychotic response to conventional antipsychotic drugs (Kaplan et al. 1990), followed by further delays in responsiveness during each
subsequent episode of treatment (Lieberman et al. 1993,
1996) and perhaps the development of a premature
dementing process (Purohit et al. 1993; Davis 1996, and
personal communication December 1995). It may be that
the initial and early progressive delays in response represent the early period of deterioration described by Breier
et al. (1991) in the first decade of the active schizophrenic
process (usually beginning during the late teens to early
twenties). According to Breier's data, after a rapid progression, the disease progresses less rapidly, if at all, during an intermediate period in the third and fourth decades,
as perhaps reflected by slower changes in VBRs (figure 2)
and a relative decrease, during middle age, of the highly
elevated PDE/PME ratios found in the twenties (figure 4).
References
Albers, M.; Meurer, H.; Marki, F.; and Klotz, J.
Phospholipase A2 activity in serum of neuroleptic-naive
psychiatric inpatients. Pharmacopsychiatry, 26:94-98,
1993.
Anderson, D.K., and Thomas, C.E. Mechanisms and the
role of oxygen free radicals in CNS pathology. In:
Racagni, G.; Brunello, N.; and Langer, S.Z., eds. Recent
Advances in the Treatment of
Neurodegenerative
Disorders and Cognitive Dysfunction. Basel, Switzerland:
Karger, 1994. pp. 119-124.
Barde, Y.A. Neurotrophins: A family of proteins supporting the survival of neurons. Progress in Clinical and
Biological Research, 390:45-56, 1994.
Barron, S.A.; Jacobs, L.; and Kinkel, W.R. Changes in
size of normal lateral ventricles during aging determined
by computerized tomography. Neurology, 26:1011-1013,
1976.
Bersani, G.; Aloe, L.; Iannitelli, A.; Maselli, P.; Venturi,
P.; Garavini, A.; Angelucci, F.; Bracci-Laudiero, L.; and
Pancheri, P. Low nerve growth factor (NGF) plasma levels in schizophrenic patients: A pilot study. Schizophrenia
Research, 18:159-160, 1996.
Breier, A.; Schreiber, J.L.; Dyer, J.; and Pickar, D.
National Institute of Mental Health longitudinal study of
chronic schizophrenia: Prognosis and predictors of outcome. Archives of General Psychiatry, 48:239-246, 1991.
Using delayed antipsychotic response as a marker to
identify the group of patients with a neurodegenerative
process, we have previously described a 10.6 percent risk
in first-degree relatives for developing a similar psychotic
process, with a similar poor prognosis (Sautter et al.
1993). Such putative familiality of the neurodegenerative
psychosis should be established using the gold standard of
premature, progressive increase in ventricular size in multiple pedigree members of neurodegenerative probands.
The possibility of identifying a susceptibility site or sites
within the human genome for the degenerative psychosis
is also intriguing. One would anticipate that the linkage
sites for the neurodegenerative psychosis might be different from the sites for other familial (genetic) forms of
schizophrenia. Such differences in genomic susceptibility
sites in the neurodegenerative, neurodevelopmental, and
dopamine psychosis pedigrees (Garver et al. 1997) would
confirm the genetic heterogeneity of the schizophrenias
(Garver et al. 1989). Moreover, one or more linkage sites
limited to probands and pedigrees widi a neurodegenerative process would be the ultimate validator for the separation of such a degenerative psychosis from the bulk of
the schizophrenias.
Carlen, PL.; Wortzman, G.; Holgate, R.C.; Wilkinson,
D.A.; and Rankin, G. Reversible cerebral atrophy in
recently abstinent chronic alcoholics measured by computed tomography scans. Science, 200:1076-1078, 1978.
Chakos, M.H.; Lieberman, J.A.; Bilder, R.M.; Borenstein,
M.; Lerner, G.; Bogerts, B.; Wu, H.; Kinon, B.; and
Ashtari, M. Increase in caudate nuclei volumes of firstepisode schizophrenic patients taking antipsychotic drugs.
American Journal of Psychiatry, 151:1430-1436, 1994.
Chang, W.H.; Chen, T.Y.; Lin, S.K.; Lung, F.W.; Lin,
W.L.; Hu, W.H.; and Yeh, E.K. Plasma catecholamine
metabolites in schizophrenics: Evidence for the two-subtype concept Biological Psychiatry, 27:510-518, 1990.
Chang, W.H.; Hwu, H.G.; Chen, T.Y.; Lin, S.K.; Lung,
F.W.; Chen, H.; Lin, W.L.; Hu, W.H.; Lin, H.N.; and
Chien, C.P. Plasma homovanillic acid and treatment
response in a large group of schizophrenic patients.
Schizophrenia Research, 10:259-265, 1993.
375
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
Artman, H.; Grau, H.; Adelman, M.; and Schleiffer, R.
Reversible and non-reversible enlargement of cerebrospinal fluid spaces in anorexia nervosa. Neurobiology,
27:304-312, 1985.
Schizophrenia Bulletin, Vol. 24, No. 3, 1998
J.L. Knoll et al.
Coffman, J.A. Computed tomography. In: Andreasen,
N.C., ed. Brain Imaging: Application in Psychiatry.
Washington, DC: American Psychiatric Association Press,
1989. pp. 1-65.
phology and cognition in first-episode schizophrenic
patients: Preliminary findings. Biological Psychiatry,
38:349-360, 1995.
Edelman, G.M., and Chuong, C M . Embryonic to adult
conversion of neural cell adhesion molecules in normal
and staggerer mice. Proceedings of the National Academy
of Sciences of the United States of America, 79:70367040, 1982.
Collins, R.C., and Olney, J.W. Focal cortical seizures
cause distant thalamic lesions. Science, 218:177-179,
1982.
Feinberg, I. Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?
Journal of Psychiatric Research, 17:319-334, 1982/83.
Conrad, A.J., and Scheibel, A.B. Schizophrenia and the
hippocampus: The embryological hypothesis extended.
Schizophrenia Bulletin, 13(4):577-587, 1987.
Frecska, E.; Losonczy, M.F.; Keefe, R.E.; Song, I.S.; Rotter, M.; Apter, S.; Guo, L.; Davidson, M.; Mohs, R.C.; and
Davis, K.L. Ventricular enlargement in poor outcome
schizophrenia: Support for asymmetric age dependent
change. [Abstract] American College of Neuropsychopharmacology, 34:74, 1995.
Cotran, R.S.; Kuman, V; and Robbins, S.L., eds. Pathologic Basis of Disease. 4th ed. Philadelphia, PA: W.B.
Saunders and Company, 1989. pp. 1-38.
Cowan, W.M.; Fawcett, J.W.; O'Leary, D.D.M.; and
Stanfield, B.B. Regressive events in neurogenesis.
Science, 225:1258-1265, 1984.
Fujimoto, T.; Nakano, T.; Takano, T.; Hokazono, Y.;
Asakura, T.; and Tsuji, T. Study of chronic schizophrenics
using 31 P magnetic resonance chemical shift imaging.
Acta Psychiatrica Scandinavica, 86:455-462, 1992.
Crow, T.J. Two dimensions of pathology in schizophrenia:
Dopaminergic and non-dopaminergic. Psychopharmacology Bulletin, 18(l):22-29, 1982.
Garver, D.L.; Kelly, K.; Fried, K.A.; Magnusson, M.; and
Hirschowitz, J. Drug response patterns as a basis of nosology for the mood-congruent psychoses (the schizophrenias). Psychological Medicine, 18:873-885,1988.
D'Amato, T; Rochet, T.; Dalery, J.; Chauchat, J.H.; Terra,
J.L.; Arteaga, C ; and Marie-Cardine, M. X-ray computed
tomographic abnormalities in schizophrenia: Trial of relationship with clinical data. Encephale, 18:175-179, 1992.
Garver, D.L.; Reich, T.; Isenberg, K.E.; and Cloninger,
C.R. Schizophrenia and the question of genetic heterogeneity. Schizophrenia Bulletin, 15(3):421^30, 1989.
Davis, K.L. "Ventricular Enlargement in Poor Outcome
Schizophrenia: Support for Asymmetric Age Dependent
Change." Paper presented at the 34th Annual Meeting of
the American College of Neuropsychopharmacology, San
Juan, Puerto Rico, December 1996.
Garver, D.L.; Steinberg, J.L.; McDermott, B.E.; Yao, J.K.;
Ramberg, J.E.; Lewis, S.; and Kingsbury, S.J. Etiologic
heterogeneity of the psychoses: Is there a dopamine psychosis? Neuropsychopharmacology, 16(3): 191-201, 1997.
Gattaz, W.F.; Hubner, C.V.; Nevalainen, TJ.; Thuren, T.;
and Kinnunen, P.K.J. Increased serum phospholipase A2
activity in schizophrenia: A replication study. Biological
Psychiatry, 28:495-501, 1990.
Deakin, J.F.W.; Slater, P.; Simpson, M.D.C.; Gilchrist,
A.C.; Skan, W.J.; Royston, M.C.; Reynolds, G.P.; and
Cross, A.J. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. Journal of Neuro chemistry, 52:1781-1786, 1989.
Gattaz, W.F.; Kollisch, M.; Thuren, T; Vutanen, J.A.; and
Kinnunen, P.K.J. Increased plasma phospholipase-A 2
activity in schizophrenic patients: Reduction after neuroleptic therapy. Biological Psychiatry, 22:421^26,1987.
Deicken, R.F.; Calabrese, G.; Merrin, E.L.; Meyerhoff,
D.J.; Dillon, W.P.; Weine, M.W.; and Fein, G.
3
'Phosphorus magnetic resonance spectroscopy of the
frontal and parietal lobes in chronic schizophrenia.
Biological Psychiatry, 36:503-510, 1994.
Gattaz, W.F.; Schmitt, A.; and Maras, A. Increased platelet
phospholipase A2 activity in schizophrenia. Schizophrenia
Research, 16:1-6, 1995.
DeLisi, L.E.; Stritzke, P.; Riordan, H.; Holan, V.; Boccio,
A.; Kushner, M.; McClelland, J.; Van Eyl, O.; and
Annand, A. The timing of brain morphological changes in
schizophrenia and their relationship to clinical outcome.
Biological Psychiatry, 31:241-254, 1992.
Gewirtz, G.; Squires-Wheeler, E.; Sharif, Z.; and Honer,
W.G. Results of computerised tomography during first
admission for psychosis. British Journal of Psychiatry,
164:789-795, 1994.
Glen, A.I.M.; Glen, E.M.T.; Horrobin, D.F.; Vaddadi,
K.S.; Spellman, M.; Morse-Fisher, N.; Ellis, K.; and
Skinner, F.S. A red cell membrane abnormality in a sub-
DeLisi, L.E.; Tew, W.; Xie, S.; Hoff, A.L.; Sakuma, M.;
Kushner, M.; Lee, G.; Shedlack, K.; Smith, A.M.; and
Grimson, R. A prospective follow-up study of brain mor-
376
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
Coffman, J.A., and Nasrallah, H.A. Relationships between
brain density, cortical atrophy and ventriculomegaly in
schizophrenia and mania. Acta Psychiatrica Scandinavica,
72:126-132,1985.
Schizophrenia Bulletin, Vol. 24, No. 3, 1998
Heterogeneity of the Psychoses
subtypes in left hippocampus in schizophrenia. Lancet,
1:583-584, 1988.
Goetz, K.L., and van Kammen, D.P. Computerized axial
tomography scans and subtypes of schizophrenia: A
review of the literature. Journal of Nervous and Mental
Disease, 141:31-41, 1986.
Keshavan, M.S.; Anderson, S.; and Pettegrew, J.W. Is
schizophrenia due to excessive synaptic pruning in the
prefrontal cortex? The Feinberg hypothesis revisited.
Journal of Psychiatric Research, 28(3):239-265, 1994.
Hitri, A.; Casanova, M.F.; Kleinman, J.E.; Weinberger,
D.R.; and Wyatt, R.J. Age-related changes in [3H]GBR
12935 binding site density in the prefrontal cortex of controls and schizophrenics. Biological
Psychiatry,
37:175-182, 1995.
Keshavan, M.S.; Pettegrew, J.W.; Panchalingam, K.S.;
Kaplan, D.; and Bozik, E. Phosphorus-31 magnetic resonance spectroscopy detects altered brain metabolism
before onset of schizophrenia. [Letter] Archives of
General Psychiatry, 48(12):1112-1113, 1991.
Hollister, J.M.; Laing, P.; and Mednick, S.A. Rhesus
incompatibility as a risk factor for schizophrenia in male
adults. Archives of General Psychiatry, 53:19-24, 1996.
Kety, S.S.; Rosenthal, D.; Wender, PH.; Shulsinger, F.;
and Jacobsen, B. Mental illness in the biological and
adoptive families of individuals who have become schizophrenic. Behavioral Genetics, 6:219-225, 1976.
Horrobin, D.F.; Manku, M.S.; Hillman, H.; Iain, A.; and
Glen, M. Fatty acid levels in the brains of schizophrenics
and normal controls. Biological Psychiatry, 30:795-805,
1991.
Klockgether, T., and Turski, L. Toward an understanding
of the role of glutamate in experimental parkinsonism:
Agonist-sensitive sites in the basal ganglia. Annals of
Neurology, 34:585-593,1993.
Huttenlocher, P.R. Synaptic density in human frontal cortex: Developmental changes and effects of aging. Brain
Research, 163:195-205, 1979.
Jaskiw, G.E.; Juliano, D.M.; Goldberg, T.E.; Hertzman,
M.; Urow-Hamell, E.; and Weinberger, D.R. Cerebral
ventricular enlargement in schizophreniform disorder
does not progress: A seven year follow-up study.
Schizophrenia Research, 14:23-28, 1994.
Lieberman, J.A.; Alvir, J.M.; Koreen, A.; Geisler, S.;
Chakos, M.; Sheitman, B.; and Woerner, M.
Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology, 14(Suppl. 3): 13—21,
19%.
Lieberman, J.A.; Jody, D.; Geisler, S.; Alvir, J.; Loebel,
A.; Szymanski, S.; Woemer, M.; and Borenstein, M. Tune
course and biologic correlates of treatment response in
first-episode schizophrenia. Archives of General
Psychiatry, 50:369-376, 1993.
Kaiya, H.; Horrobin, D.F.; Manku, M.S.; and MorseFisher, N. Essential and other fatty acids in plasma in
schizophrenics and normal individuals from Japan.
Biological Psychiatry, 30(4):357-362, 1991.
Loebel, A.; Lieberman, J.A.; Alvir, J.; Geisler, S.; Koreen,
A.; and Chakos, M. Time to treatment response in successive episodes of early-onset schizophrenia. [Abstract]
Schizophrenia Research, 15:158, 1995.
Kaplan, M.J.; Lazoff, M.; Kelly, K.; Lukin, R.; and
Garver, D.L. Enlargement of cerebral third ventricle in
psychotic patients with delayed response to neuroleptics.
Biological Psychiatry, 27:205-214, 1990.
Kato, T.; Shioiri, T.; Murashita, J.; Hamakawa, H.;
Inubushi, T.; and Takahashi, S. Lateralized abnormality of
high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia.
Psychiatry Research: Neuroimaging, 61(3): 151—160,
1995.
Luchins, D.J.; Lewine, R.RJ.; and Meltzer, H.Y. Lateral
ventricular size, psychopathology, and medication
response in the psychoses. Biological Psychiatry, 19:2945,1984.
Mahadik, S.P.; Mukherjee, S.; Correnti, E.E.; and
Scheffer, R. Elevated levels of lipid peroxidation products
in plasma of drug-naive patients at the onset of psychosis.
[Abstract] Schizophrenia Research, 15:66, 1995.
Kemali, D.; Maj, M.; Galderisi, S.; Milici, N.; and Salvati,
A. Ventricle-to-brain ratio in schizophrenia: A controlled
follow-up study. Biological Psychiatry, 26:756-759, 1989.
Kerr, J.F.; Wyllie, A.H.; and Currie, A.R. Apoptosis: A
basic biological phenomenon with wide-ranging implications in tissue kinetics. British Journal of Cancer, 26:239—
257, 1972.
Kerwin, R.W.; Patel, S.; Meldrum, B.S.; Czudek, C ; and
Reynolds, G.P. Asymmetrical loss of glutamate receptor
377
Mednick, S.A.; MaChon, R.A.; Huttunen, M.O.; and
Bonett, D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Archives of General
Psychiatry, 45(2): 189-192,1988.
Mitchell, I.J.; Lawson, S.; Moser, B.; Laidlaw, S.M.;
Cooper, A.J.; Walkinshaw, G.; and Waters, C M .
Glutamate-induced apoptosis results in a loss of striatal
neurons in the Parkinsonian rat. Neuroscience, 63:1-5,
1994.
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
group of schizophrenic patients: Evidence for two diseases. Schizophrenia Research, 112:53-61, 1994.
Schizophrenia Bulletin, Vol. 24, No. 3, 1998
J.L. Knoll et al.
Mukherjee, S.; Mahadik, S.P.; Correnti, E.E.; and
SchefFer, R. The antioxidant defense system at the onset
of psychosis. Biological Psychiatry, 35:615-747, 1994.
Toffano, G., eds. New Research Strategies in Biological
Psychiatry. London, England: John Libbey, 1984.
Pulver, A.E.; Lasseter, V.K.; Kasch, L.; Wolyniec, P.;
Nestadt, G.; Blouin, J.; Kimberland, M.; Babb, R.;
Vourlis, S.; Chen, H.; Lalioti, M.; Morris, M.A.;
Karayiorgou, M.; Ott, J.; Meyers, D.; Antonarakis, S.E.;
Housman, D.; and Kazazian, H.H. Schizophrenia: A
genome scan targets chromosomes 3p and 8p as potential
sites of susceptibility genes. American Journal of Medical
Genetics, 60(3):252-260, 1995.
Nasrallah, H.A.; Jacoby, C.G.; Chapman, S.; and
McCalley-Whitters, M. Third ventricular enlargement on
CT scans in schizophrenia: Association with cerebellar
atrophy. Biological Psychiatry, 20:445-450,1985.
Noponen, M.; Sanfilipo, M.; Samanich, K.; Ryer, H.; Ko,
G.; Angrist, B.; Wolkin, A.; Duncan, E.; and Rotrosen, J.
Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biological Psychiatry, 34:641-649,
1993.
O'Donnell, B.F.; Faux, S.F.; McCarley, R.W.; Kimble,
M.O.; Salisbury, D.F.J Nestor, P.G.; Kikinis, R.; Jolesz,
F.A.; and Shenton, M.E. Increased rate of of P300 latency
prolongation with age in schizophrenia. Archives of
General Psychiatry, 52:544-549, 1995.
Raff, M.C.; Barres, B.A.; Burne, J.F.; Coles, H.S.;
Ishizaki, Y.; and Jacobson, D. Programmed cell death and
the control of cell survival: Lessons from the nervous system. Science, 262:695-700, 1993.
Olney, J.W., and Farber, N.B. Glutamate receptor dysfunction and schizophrenia. Archives of General
Psychiatry, 52:998-1007, 1995.
Rothman, S.M., and Olney, J.W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Annals of
Neurology, 19:105-111, 1986.
Pandurangi, A.K.; Goldberg, S.C.; Brink, D.D.; Hill,
M.H.; Gulati, A.N.; and Hamer, R.M. Amphetamine challenge test, response to treatment, and lateral ventricle size
in schizophrenia. Biological Psychiatry, 25:207-214,
1989.
Sandyk, R.; Kay, S.R.; and Merriam, A.E. Atrophy of the
cerebellar vermis: Relevance to the symptoms of schizophrenia. International Journal of Neuroscience, 57:205—
212, 1991.
Pangerl, A.M.; Stuedle, A.; Jaroni, H.W.; and Gattaz, W.F.
Increased lysophosphatidylcholine content in platelet
membrane of schizophrenics. Schizophrenia Research,
6:134-135,1992.
Sautter, F.; McDermott, B.; and Garver, D. Familial differences between neuroleptic response psychosis and
delayed neuroleptic response psychosis. Biological Psychiatry, 33:15-21, 1993.
Peralta, V.; deLeon, J.; and Cuesta, M.J. Are there more
than two syndromes in schizophrenia? A critique of the
positive-negative dichotomy. British Journal of
Psychiatry, 161:335-343, 1992.
SchefFer, R.; Mahadik, S.P.; Correnti, E.E.; McClure, M.;
and Mukherjee, S. Membrane lipid peroxidation and neurological signs in first episode psychosis. [Abstract]
Biological Psychiatry, 37:681, 1995.
Perez-Polo, J.R.; Dy, P.; Westlund, K.; Hall, K.; and
Livingston, K. Levels of serum nerve growth factor in
schizophrenia. In: Bergsma, D., and Goldstein, A.L., eds.
Birth Defects: Original Article Series. Vol. 14, No. 5.
New York, NY: Liss, 1978. pp. 311-321.
Schwarzkopf, S.B.; Olson, S.C.; Coffman, J.A.; and
Nasrallah, H.A. Third and lateral ventricular volumes in
schizophrenia: Support for progressive enlargement of
both structures. Psychopharmacology
Pettegrew, J.W.; Keshavan, M.S.; and Minshew, NJ. 31 P
nuclear magnetic resonance spectroscopy: Neurodevelopment and schizophrenia. Schizophrenia Bulletin,
19(l):35-53, 1993.
Shioiri, T.; Kato, T.; Inubushi, T.; Murashita, J.; and
Takahashi, S. Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy
in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Research: Neuroimaging, 55(4):223-235,
1994.
Pettegrew, J.W.; Keshavan, M.S.; Panchalingam, K.;
Strychor, S.; Kaplan, D.B.; Tretta, M.G.; and Allen, M.
Alterations in brain high-energy phosphate and membrane
phospholipid metabolism in first-episode, drug-naive
schizophrenics. Archives of General
Bulletin,
26{3):385-391,1990.
Psychiatry,
Shoulson, I. Huntington's disease: Anti-neurotoxic therapeutic strategies. In: Fuxe, K.; Roberts, P.; and Schwarcz,
R., eds. Excitotoxins. London: Macmillan Press, 1983.
pp. 343-353.
48:563-568, 1991.
Prilipko, L.L. Activation of lipid peroxidation under stress
and in schizophrenia. In: Kenali, D.; Morozov, P.V.; and
378
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
Purohit, D.P.; Davidson, M.; Perl, D.P.; Powchik, P.;
Haroutunian, V.H.; Bierer, L.M.; McCrystal, J.; Losonczy,
M.; and Davis, K.L. Severe cognitive impairment in
elderly schizophrenic patients: A clinicopathological
study. Biological Psychiatry, 33:255-260, 1993.
Heterogeneity of the Psychoses
Schizophrenia Bulletin, Vol. 24, No. 3, 1998
SigmaPlotfor Windows. San Rafael, CA. Jandel Scientific,
1986-1994.
Simon, R.P.; Swan, J.H.; Griffiths, T.; and Meldrum, B.S.
Blockade of //-methyl-D-aspartate receptors may protect
against ischemic damage in the brain. Science, 226:850852, 1984.
Simpson, M.D.C.; Simpson, P.S.; Royston, M.C.; and
Deakin, J.F.W. Regionally selective deficits in uptake sites
for glutamate and gamma-aminobutyric acid in the basal
ganglia in schizophrenia. Psychiatry Research, 42:273282, 1992.
Wood, K.A., and Youle, RJ. Apoptosis and free radicals.
Annals of the New York Academy of Sciences, 738:400407, 1994.
Woods, B.T.; Yurgelun-Todd, D.; Benes, F.M.;
Frankenburg, F.R.; Pope, H.G., Jr.; and McSparren, J.
Progressive ventricular enlargement in schizophrenia:
Comparison to bipolar affective disorder and correlation
with clinical course. Biological Psychiatry, 27:341-352,
1990.
Wyatt, R.J. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin, 17(2):325-351, 1991.
Stanley, J.A.; Williamson, P.C.; Drost, D.J.; Carr, T.J.;
Rylett, R.J.; Morrison-Stewart, S.; and Thompson, R.T.
Membrane phospholipid metabolism and schizophrenia:
An in vivo 31 P-MR spectroscopy study. Schizophrenia
Research, 13:209-216, 1994.
Yao, J.K.; van Kammen, D.P.; and Welker, J.A. Red blood
cell membrane dynamics in schizophrenia: n. Fatty acid
composition. Schizophrenia Research, 13:217-226, 1994.
Stevens, J.R. Abnormal reinnervation as a basis for schizophrenia: A hypothesis. Archives of General Psychiatry,
49:238-243,1992.
Acknowledgments
Susser, E.; Neugebauer, R.; Hoek, H.W.; Brown, A.S.;
Lin, S.; Labovitz, D.; and Gorman, J.M. Schizophrenia
after prenatal famine: Further evidence. Archives of
General Psychiatry, 53:25-31, 1996.
This research was supported in part by grant MH-42666
to Dr. Garver from the National Institute of Mental
Health, a Department of Veterans Affairs Merit Review to
Dr. Garver, and the Southwestern Medical Center John
Schermerhorn Psychiatric Fund.
SYSTAT. Statistics. Version 5 edition. Evanston, IL:
SYSTAT, Inc., 1992.
The Authors
Vita, A.; Died, M.; Giobbio, G.M.; Azzone, P.; Garbarini,
M.; Sacchetti, E.; Cesana, B.M.; and Cazzullo, C.L. CT
scan abnormalities and outcome of chronic schizophrenia.
American Journal of Psychiatry, 148:1577-1579, 1991.
James L. Knoll IV, M.D., is Psychiatry Resident,
Southwestern Medical Center, University of Texas,
Dallas, TX. David L. Garver, M.D., is Communities
Foundation Trust Professor of Brain Science,
Southwestern Medical Center, University of Texas, Dallas
TX, Director of Research, Mental Health, Dallas Veterans
Affairs Medical Center (VAMC), Director, National
Clozapine Coordinating Center, Dallas VAMC, and Staff
Physician, Dallas VAMC, Dallas, TX. Jane E. Ramberg,
M.S., is a Research Assistant, Dallas VAMC. Steven J.
Kingsbury, M.D., Ph.D., is Staff Psychiatrist/
Psychologist, Dallas VAMC, and Assistant Professor in
the Departments of Psychiatry and Psychology,
Southwestern Medical Center, University of Texas,
Dallas, TX. Deborah Croissant, M.S., B.S.N., is a
Research Assistant, Southwestern Medical Center,
University of Texas, Dallas, TX. Barbara McDermott,
Ph.D., is Associate Professor of Psychiatry and
Neurology, Department of Psychiatry and Neurology,
Tulane University Medical School, New Orleans, LA.
Vita, A.; Giobbio, G.M.; Dieci, M.; Garbarini, M.;
Morgant, C ; Comazzi, M.; and Invernizz, G. Stability of
cerebral ventricular size from the appearance of the first
psychotic symptoms to the later diagnosis of schizophrenia. Biological Psychiatry, 35:960-962, 1994.
Vita, A.; Sacchetti, E.; Calzeroni, A.; and Cazzullo, C.L.
Cortical atrophy in schizophrenia: Prevalence and associated features. Schizophrenia Research, 1:329-337, 1988.
Waddington, J.L.; O'Callaghan, E.; Buckley, P.; Larkin,
C ; Redmond, O.; Stack, J.; and Ennis, J.T. The age dependencies of MRI abnormalities in schizophrenia suggest
early ventricular enlargement but later prominence of cortical atrophy. Schizophrenia Research, 5:188-189, 1991.
Wang, S.; Sun, C ; Walczak, C.A.; Ziegle, J.S.; Kipps,
B.R.; Goldin, L.R.; and Diehl, S. Evidence for a suscepti-
379
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015
Stanley, J.A.; Williamson, P.C.; Drost, D.J.; Carr, T.J.;
Rylett, J.; Malla, A.; and Thompson, R.T. An in vivo study
of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance
spectroscopy. Archives of General Psychiatry, 52:399406,1995.
bility locus for schizophrenia on chromosome 6pter-p22.
Nature Genetics, 10(l):41-46, 1995.
Weinberger, D.R.; Bigelow, L.B.; Kleinman, J.E.; Klein,
S.T.; Rosenblatt, J.E.; and Wyatt, R.J. Cerebral ventricular
enlargement in chronic schizophrenia: An association
with poor response to treatment. Archives of General Psychiatry, 37:11-13, 1980.
Downloaded from http://schizophreniabulletin.oxfordjournals.org/ by guest on December 28, 2015